Analyst Ratings For GE HealthCare Techs

Loading...
Loading...

Throughout the last three months, 4 analysts have evaluated GE HealthCare Techs GEHC, offering a diverse set of opinions from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 0 2 0 1
Last 30D 1 0 0 0 0
1M Ago 0 0 0 0 0
2M Ago 0 0 0 0 0
3M Ago 0 0 2 0 1

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $79.0, along with a high estimate of $96.00 and a low estimate of $66.00. Highlighting a 8.14% decrease, the current average has fallen from the previous average price target of $86.00.

Investigating Analyst Ratings: An Elaborate Study

A comprehensive examination of how financial experts perceive GE HealthCare Techs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Anthony Petrone Mizuho Raises Buy $96.00 $94.00
Patrick Wood Morgan Stanley Lowers Equal-Weight $74.00 $78.00
Matthew Taylor Jefferies Announces Hold $80.00 -
Graham Doyle UBS Lowers Sell $66.00 $86.00

Key Insights:

Loading...
Loading...
  • Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to GE HealthCare Techs. This offers insight into analysts' perspectives on the current state of the company.
  • Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of GE HealthCare Techs compared to the broader market.
  • Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of GE HealthCare Techs's stock. This examination reveals shifts in analysts' expectations over time.

To gain a panoramic view of GE HealthCare Techs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on GE HealthCare Techs analyst ratings.

Get to Know GE HealthCare Techs Better

GE HealthCare Technologies Inc is a globally medical technology, pharmaceutical diagnostics, and digital solutions innovator company. It has four operating segments; Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). It earns a majority of its revenue from the Imaging segment.

GE HealthCare Techs: Delving into Financials

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Revenue Growth: GE HealthCare Techs displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 5.38%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: GE HealthCare Techs's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 7.78%, the company may face hurdles in effective cost management.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.27%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): GE HealthCare Techs's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.16%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: GE HealthCare Techs's debt-to-equity ratio stands notably higher than the industry average, reaching 1.44. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

The Core of Analyst Ratings: What Every Investor Should Know

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
date
▲▼
ticker
▲▼
name
▲▼
Price Target
▲▼
Upside/Downside
▲▼
Recommendation
▲▼
Firm
▲▼
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...